Research programme: anti-inflammatory therapeutics - Emerald BioStructures/UCB
Latest Information Update: 12 Jan 2011
At a glance
- Originator Emerald BioStructures; UCB
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Inflammation
Most Recent Events
- 08 Jan 2011 Early research is ongoing in USA
- 06 Feb 2009 Early research in Inflammation in USA (unspecified route)